SecBot SecBot
6-K ·Filed Nov 2, 2026

BWAY

Brainsway Ltd.
NEUTRAL
Impact 3/10
Horizonmonths Processed14d 14h ago SEC0001171843-26-007014
Notable filing: 6-K
Actionable Insight • Neutral

Monitor for future revenue contributions from the MHS collaboration and the Heading Health investment, as well as any updates on the adoption of the SWIFT protocol. The filing does not provide financial metrics, so the next quarterly earnings release will be key to assess the impact of these strategic initiatives.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$11.09
T+0 close · Nov 2, 2026 · via day close
Latest settled
+4.96%
T+5 · $11.64 · next T+20 in 14d
Vs SPY
+4.88%
α at T+5
Latest observation
−9.59%
T+9 · FF3 residual α
  1. T+0 · Nov 2 $11.09entry
  2. T+1 · 14d ago +0.54%α +0.24% · $11.15
  3. T+5 · 8d ago +4.96%α +4.88% · $11.64
  4. T+10 · todayOpen
  5. T+20 · in 14d Pending
  6. T+60 · in 2mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BrainsWay announced a strategic collaboration with Mindful Health Solutions (MHS), a behavioral health provider now part of Radial Health's network of 27 brain medicine clinics. The collaboration aims to expand patient access to BrainsWay's Deep TMS and the recently FDA-cleared SWIFT protocol, and explore integration of Neurolief's ProlivRx at-home therapy. Separately, BrainsWay made a $0.8M follow-on equity investment in the management services organization servicing the Heading Health clinic network. No financial results or guidance were provided in this filing.

Key Facts

  • Strategic collaboration with Mindful Health Solutions (MHS), now part of Radial Health's network of 27 brain medicine clinics across 7 states.
  • Collaboration covers BrainsWay Deep TMS, the recently FDA-cleared accelerated SWIFT treatment protocol, and potential integration of Neurolief's ProlivRx at-home therapy.
  • BrainsWay made a follow-on equity investment of $0.8M in the management services organization servicing the Heading Health clinic network.
  • No financial results, revenue, EPS, or guidance were disclosed in this filing.

Financial Impact

Follow-on equity investment of $0.8M in a management services organization; no revenue or profit impact stated.

Risk Factors

  • The collaboration and investment may not generate material revenue or profitability improvements.
  • Forward-looking statements caution that investments in management services organizations may not produce profitable returns.
  • No financial data or guidance was provided, limiting the ability to assess the near-term financial impact.

Market Snapshot

Exchange
OTC
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-007014
Document: f6k_110126.htm0001171843-26-007014
Document: 0001171843-26-007014-index-headers.html0001171843-26-007014
Document: 0001171843-26-007014-index.html0001171843-26-007014
Document: 0001171843-26-007014.txt0001171843-26-007014
Earnings Context (Synthetic; results releases only)0001171843-26-007014

Track record

24 reports on BWAY

Performance horizon

6 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +27.55% at T+60 after the Mar 4, 2026 report. 8 of 11 went positive at some point.

Filters
  1. Nov 10, 20266d ago 6-K Bullish 6/10 No price data
  2. Nov 10, 20266d ago 6-K Neutral 5/10 Entry $10.67 Now $9.39 −12.00% settles Dec 9
  3. Nov 2, 202614d ago 6-K Neutral 3/10 Viewing Entry $11.09 Now $9.39 −15.33% settles Dec 1
  4. Nov 2, 202614d ago Press Release Neutral 3/10 Entry $11.09 Now $9.39 −15.33% settles Dec 1
  5. Oct 26, 202621d ago 6-K Neutral 3/10 Entry $11.21 Now $9.39 −16.24% settles Nov 23
  6. Oct 21, 202626d ago 6-K Neutral 3/10 Entry $11.44 Now $9.39 −17.92% settles Nov 19
  7. Oct 19, 202628d ago 6-K Neutral 3/10 Entry $11.99 to $9.39 Now $9.39 −21.68% ▼ −21.68% −18.22% vs SPY
  8. Oct 19, 202628d ago Press Release Neutral 4/10 Entry $11.99 to $9.39 Now $9.39 −21.68% ▼ −21.68% −18.22% vs SPY
  9. Oct 13, 20264w ago 6-K Neutral 4/10 Entry $11.92 to $10.67 Now $9.39 −21.22% ▼ −10.49% −6.88% vs SPY
  10. Sep 8, 20269w ago 6-K Neutral 4/10 Entry $14.16 to $11.89 Now $9.39 −33.69% ▼ −16.03% −18.00% vs SPY
Showing 10 of 24

US Market Status

Market Closed · Opens Wed (11h 45m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026